JP2024529976A5 - - Google Patents
Info
- Publication number
- JP2024529976A5 JP2024529976A5 JP2024505311A JP2024505311A JP2024529976A5 JP 2024529976 A5 JP2024529976 A5 JP 2024529976A5 JP 2024505311 A JP2024505311 A JP 2024505311A JP 2024505311 A JP2024505311 A JP 2024505311A JP 2024529976 A5 JP2024529976 A5 JP 2024529976A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- mutation
- pharmaceutical composition
- inhibitor
- immunotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163227111P | 2021-07-29 | 2021-07-29 | |
| US63/227,111 | 2021-07-29 | ||
| US202163280430P | 2021-11-17 | 2021-11-17 | |
| US63/280,430 | 2021-11-17 | ||
| PCT/US2022/038903 WO2023009834A2 (en) | 2021-07-29 | 2022-07-29 | Methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024529976A JP2024529976A (ja) | 2024-08-14 |
| JP2024529976A5 true JP2024529976A5 (enExample) | 2025-08-04 |
Family
ID=85088302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024505311A Pending JP2024529976A (ja) | 2021-07-29 | 2022-07-29 | がんを治療する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240374605A1 (enExample) |
| EP (1) | EP4376886A4 (enExample) |
| JP (1) | JP2024529976A (enExample) |
| WO (1) | WO2023009834A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017087885A1 (en) | 2015-11-19 | 2017-05-26 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers |
| US11497752B2 (en) | 2018-01-30 | 2022-11-15 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020081588A1 (en) | 2018-10-17 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Swi/snf family chromatin remodeling complexes and uses thereof |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| AU2021213811A1 (en) | 2020-01-29 | 2022-07-28 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US12606553B2 (en) | 2021-03-09 | 2026-04-21 | Foghorn Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
| WO2024086577A1 (en) * | 2022-10-17 | 2024-04-25 | Foghorn Therapeutics Inc. | Methods of reducing or preventing metastases |
| WO2025080767A1 (en) * | 2023-10-10 | 2025-04-17 | Foghorn Therapeutics Inc. | Differentiation and maintenance dosing regimen for fhd 286 (brg1/brm inhibitor) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014150751A2 (en) * | 2013-03-15 | 2014-09-25 | Novartis Ag | Biomarkers associated with brm inhibition |
| US10864258B2 (en) * | 2013-04-29 | 2020-12-15 | Trustees Of Dartmouth College | Method for treating pancreatic cancer with Toxoplasma gondii vaccine |
| US11497752B2 (en) * | 2018-01-30 | 2022-11-15 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| JP2022508155A (ja) * | 2018-11-21 | 2022-01-19 | フォグホーン セラピューティクス インコーポレイテッド | がんを治療する方法 |
| AU2021213811A1 (en) * | 2020-01-29 | 2022-07-28 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
-
2022
- 2022-07-29 US US18/292,582 patent/US20240374605A1/en active Pending
- 2022-07-29 WO PCT/US2022/038903 patent/WO2023009834A2/en not_active Ceased
- 2022-07-29 JP JP2024505311A patent/JP2024529976A/ja active Pending
- 2022-07-29 EP EP22850374.4A patent/EP4376886A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024529976A5 (enExample) | ||
| Petroni et al. | Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment | |
| Mohseni et al. | Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications | |
| JP6595024B2 (ja) | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 | |
| JP6288726B2 (ja) | 変異ｆｌｔ３増殖性障害の治療剤クレノラニブ（ｃｒｅｎｏｌａｎｉｂ） | |
| JP2023512039A5 (enExample) | ||
| JP2022523074A5 (enExample) | ||
| JP2022176316A (ja) | 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法 | |
| RU2747788C2 (ru) | Комбинированная терапия ингибиторами notch и cdk4/6 для лечения рака | |
| RU2020114632A (ru) | Терапевтические способы, относящиеся к ингибиторам hsp90 | |
| US20250041297A1 (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
| JP6911048B2 (ja) | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 | |
| CN113164779A (zh) | 治疗cdk4/6抑制剂耐药性癌症的方法 | |
| TW202332431A (zh) | 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 | |
| JP2023521227A5 (enExample) | ||
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2025533719A (ja) | がんの治療のためのｋａｔ６阻害剤を含む投与レジメン | |
| ES3037206T3 (en) | Combination therapy | |
| WO2020236668A1 (en) | Leukadherin-1 alone or in combination for use in the treatment of cancer | |
| TW200922595A (en) | Organic compounds | |
| CN117427186A (zh) | 抗her2抗体药物偶联物联合抗pd-l1抗体在制备治疗肺癌的药物中的用途 | |
| CN119497613A (zh) | 使用lsd1抑制剂治疗nf1-突变肿瘤的方法 | |
| TW202200147A (zh) | Ｂｅｌｖａｒａｆｅｎｉｂ用於癌症治療 | |
| Jaibu et al. | Targeted cancer therapy: Promises and reality | |
| Goldman et al. | P47. 03 Telisotuzumab vedotin monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer: Stage 2 |